Immucell (ICCC) Net Cash Flow (2010 - 2025)

Immucell (ICCC) has reported Net Cash Flow for 16 consecutive years, with -$79367.0 the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Net Cash Flow fell 57.47% year-over-year to -$79367.0; the trailing twelve-month figure through Dec 2025 stood at $48599.0 (down 98.25% YoY), and the FY2025 full-year result was $48599.0, down 98.25% from the prior year.
• Net Cash Flow improved to -$79367.0 in Q4 2025 per ICCC's latest filing, from -$2.1 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $3.9 million in Q2 2021 and bottomed at -$3.0 million in Q4 2022.
• Historically, Net Cash Flow has averaged -$157155.3 across 5 years, with a median of -$111327.0 in 2021.
• The sharpest annual moves came in 2022 and 2025: Net Cash Flow tumbled 981.81% in 2022, then surged 4672.9% in 2025.
• Over 5 years, Net Cash Flow stood at -$310291.0 in 2021, then sank by 878.5% to -$3.0 million in 2022, then soared by 66.71% to -$1.0 million in 2023, then soared by 95.01% to -$50401.0 in 2024, then slumped by 57.47% to -$79367.0 in 2025.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$79367.0, -$2.1 million, and $1.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.